Aya Maekawa

Aya Maekawa

Auto-generated profile, based on publicly available information

Aya Maekawa

Hepato‐Pancreato‐Biliary and Liver Transplant Surgery Unit, Department of Surgical, Oncological and Gastroenterological Sciences (DISCOG) University of Padua Padua Italy

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 November 2020 in Cell
Verified
Journal Article
Closed access
KKKenta Kawasaki
Kenta Kawasaki
KTKohta Toshimitsu
Kohta Toshimitsu
MMMami Matano
Mami Matano
MFMasashi Fujita
Masashi Fujita
MFMasayuki Fujii
Masayuki Fujii
TSToshiro Sato
Toshiro Sato


27 January 2025 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
AMAya Maekawa
Aya Maekawa
KOKojiro Omiya
Kojiro Omiya
AOAtsushi Oba
Atsushi Oba
YIYosuke Inoue
Yosuke Inoue
YHYuki Hirose
Yuki Hirose
YTYu Takahashi
Yu Takahashi

21 March 2021 in Annals of Gastroenterological Surgery
Verified
Journal Article
Open access
PDF file
YMYoshiki Murase
Yoshiki Murase
AKAtsushi Kudo
Atsushi Kudo
KAKeiichi Akahoshi
Keiichi Akahoshi
AMAya Maekawa
Aya Maekawa
YIYoshiya Ishikawa
Yoshiya Ishikawa
MTMinoru Tanabe
Minoru Tanabe
Background: Little research is available regarding the treatments combining surgical resection with systemic chemotherapy for advanced pancreatic neuroendocrine neoplasm patients. We retrospectively elucidated whether sunitinib administration before surgery in advanced pancreatic neuroendocrine neoplasm (Pan‐NEN) patients increases survival.Methods: This study included 106 of 326 Pan‐NEN patients with distant metastases and/or unresectable locally advanced tumors who visited our department to receive sunitinib for more than 1 mo during April 2002 to December 2019. Risk factors for overall survival (OS) and disease‐free survival (DFS) were analyzed.Results: The median duration of preoperative sunitinib administration and observation time after sunitinib were 6 and 26.5 mo, respectively. Of 106 patients, 31 (29.2%) underwent surgery following sunitinib administration. Hepatectomy, synchronous hepatopancreatectomy, pancreatectomy, and lymphadenectomy were performed for 13, 12, 5, and 1 patient, respectively. The 5‐y OS rates in the resected and nonresected groups were 88.9% and 14.1%, respectively (P < .001). In the multivariate analysis, the absence of surgical resection following sunitinib (hazard ratio [HR], 13.1; P = .001), poor differentiation (HR, 5.5; P = .007), and bilateral liver metastases (HR, 3.7; P = .048) were independent risk factors for OS, although large liver tumor volumes were more evident in the nonresected group, as patient characteristics. The median DFS was 16.1 mo in 22 patients who underwent R0/1 resections, and risk factors for postoperative recurrence were Ki‐67 index >7.8% (HR, 7.4; P = .02) and R1 resection (HR, 4.4; P = .04).Conclusion: Surgical resection after sunitinib administration improved OS in advanced Pan‐NENs.

15 March 2025 in HPB
Verified
Journal Article
Closed access
HIHiroyuki Ishida
Hiroyuki Ishida
TSThomas Frederik Stoop
Thomas Frederik Stoop
AOAtsushi Oba
Atsushi Oba
PBPhilippe Bachellier
Philippe Bachellier
DBDaisuke Ban
Daisuke Ban
NZNicholas J. Zyromski
Nicholas J. Zyromski

1 October 2024 in Pancreatology
Verified
Journal Article
Closed access
YHYuki Hirose
Yuki Hirose
AOAtsushi Oba
Atsushi Oba
MTManabu Takamatsu
Manabu Takamatsu
THTsuyoshi Hamada
Tsuyoshi Hamada
TTTsuyoshi Takeda
Tsuyoshi Takeda
YTYu Takahashi
Yu Takahashi